3 enrolling by invitation. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 3 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures SPN-817 - Focal Onset Seizures | Phase 2 | Enrolling by invitation | Supernus Pharmaceuticals, Inc. | 100 | 2025-07-30 | 2026-10-27 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet Atorvastatin 10mg, Modification of dietary fat composition - Epilepsy, Dyslipidemia | Phase 1 / Phase 2 | Enrolling by invitation | Johns Hopkins University | 22 | 2024-10-04 | 2026-10-19 |
| Long-term Safety and Tolerability of BHV-7000 BHV-7000 - Focal Epilepsy | Phase 2 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 660 | 2024-07-30 | 2026-05-01 |
Epilepsies, Partial (2) · Seizures (2) · Drug Resistant Epilepsy (1) · Dyslipidemias (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Nervous System Diseases (3) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Lipid Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Atorvastatin (1)
Biohaven Therapeutics Ltd. (1) · Johns Hopkins University (1) · Supernus Pharmaceuticals, Inc. (1)
United States (3) · Australia (2) · Argentina (1) · Austria (1) · Belgium (1) · Chile (1) · Croatia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1)
Maciej Gasior, MD, PhD (1) · Tanya J McDonald, MD, PhD (1)
2023 (1)